Emerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon

Simple item page
dc.catalogadorjlo
dc.contributor.authorArnold Álvarez, Jorge Ignacio
dc.contributor.authorIdalsoaga Ferrer, Francisco Javier
dc.contributor.authorDiaz Piga, Luis Antonio
dc.contributor.authorCabrera García, Daniel Alejandro
dc.contributor.authorBarrera Álvarez, Francisco Benjamín
dc.contributor.authorArab Verdugo, Juan Pablo
dc.contributor.authorArrese Jiménez, Marco Antonio
dc.date.accessioned2024-11-20T14:55:32Z
dc.date.available2024-11-20T14:55:32Z
dc.date.issued2024
dc.description.abstractPurpose of Review Metabolic dysfunction–associated steatotic liver disease (MASLD) and its aggressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and can lead to fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. Currently, there is no approved pharmacological treatment for MASLD. In this review, we aim to summarize recent data on therapeutic agents under study in phase 2 and 3 trials.Recent FindingsBuilding on a better understanding of MASLD/MASH pathophysiology, a myriad of drugs has been developed. Recent results from clinical trials show promise, with some candidates demonstrating positive outcomes in phase 3 trials that are predictably expected to be approved in the near future. Notably, resmetirom, a thyroid receptor β agonist, is likely to be approved in 2024.SummaryIn the coming years, results from several landmark trials will be available and will likely provide options to prevent progression to cirrhosis and adverse liver outcomes in patients with MASLD/MASH.
dc.format.extent16 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1007/s11901-023-00629-0
dc.identifier.eissn2195-9595
dc.identifier.urihttps://doi.org/10.1007/s11901-023-00629-0
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/88614
dc.information.autorucEscuela de Medicina; Arnold Álvarez, Jorge Ignacio; 0000-0003-2139-5120; 1148388
dc.information.autorucEscuela de Medicina; Idalsoaga Ferrer, Francisco Javier; S/I; 1017394
dc.information.autorucEscuela de Medicina; Diaz Piga, Luis Antonio; 0000-0002-8540-4930; 179253
dc.information.autorucEscuela de Medicina; Cabrera García, Daniel Alejandro; 0000-0002-5891-0459; 126029
dc.information.autorucEscuela de Medicina; Barrera Álvarez, Francisco Benjamín; S/I; 1240448
dc.information.autorucEscuela de Medicina; Arab Verdugo, Juan Pablo; 0000-0002-8561-396X; 132745
dc.information.autorucEscuela de Medicina; Arrese Jiménez, Marco Antonio; 0000-0002-0499-4191; 76095
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final219
dc.pagina.inicio204
dc.revistaCurrent Hepatology Reports
dc.rightsacceso restringido
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleEmerging Drug Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Glimpse into the Horizon
dc.typeartículo
dc.volumen23
sipa.codpersvinculados1148388
sipa.codpersvinculados1017394
sipa.codpersvinculados179253
sipa.codpersvinculados126029
sipa.codpersvinculados1240448
sipa.codpersvinculados132745
sipa.codpersvinculados76095
sipa.trazabilidadORCID;2024-01-08
Files
Collections
Artículos de revistas